{"nctId":"NCT01053247","briefTitle":"Study of 0416 Ointment in the Treatment of Atopic Dermatitis","startDateStruct":{"date":"2008-01"},"conditions":["Atopic Dermatitis"],"count":793,"armGroups":[{"label":"Test","type":"EXPERIMENTAL","interventionNames":["Drug: 0416"]},{"label":"Reference","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tacrolimus ointment 0.1%"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle of 0416 test product"]}],"interventions":[{"name":"0416","otherNames":[]},{"name":"Vehicle of 0416 test product","otherNames":[]},{"name":"tacrolimus ointment 0.1%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of Atopic Dermatitis\n* Good health with the exception of Atopic Dermatitis\n* Percent Body Surface Area minimum requirements\n\nExclusion Criteria:\n\n* Subjects who are pregnant, nursing, or planning a pregnancy within the study participation period.\n* Subjects who have any systemic or dermatological disorders with the exception of Atopic Dermatitis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"The Mean Change From Baseline in the Total Individual Clinical Signs and Symptoms Per Body Region, the Mean Change From Baseline in Pruritus and Mean Change From Baseline in the Percentage Total Body Surface Affected (%BSA).","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":269},"commonTop":["Application Site Pruritus","Application Site Irritation","Atopic Dermatitis"]}}}